Japan Approves World’s First Esophageal Cancer Viral Therapy TeroMira, Ushering in Oncolytic Virus Era

On May 22, 2026, the Japanese MHLW expert committee formally approved TeroMira, developed by Oncolys Biopharma, for esophageal cancer, making it the world’s first approved oncolytic viral therapy for esophageal cancer.

TeroMira is a genetically modified virus with precise tropism for esophageal cancer cells, replicating selectively in tumor cells to induce oncolysis without harming normal tissue. Administered intraluminally with radiotherapy, Phase III trials showed significant tumor regression in half the patients, outperforming conventional chemoradiation.

Esophageal cancer treatment relies heavily on surgery, radiotherapy and chemotherapy; advanced disease has a poor prognosis with 5‑year survival <20%. TeroMira establishes a new “oncolytic virus + radiotherapy” paradigm, offering long‑term survival hope for advanced patients and pivotal clinical evidence for oncolytic viruses in solid tumors.